Faculty of Medicine

Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14

Browse

Settings

Language: search.filters.language.English (United States)Subject: search.filters.subject.lung cancer

Search Results

Now showing 1 - 3 of 3
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    REVIEW OF LUNG CANCER PATIENT CHARACTERISTICS AND TREATMENT STRATEGIES IN THE PANDEMIC COVID-19 YEAR Treated at the University Clinic of Radiotherapy and Oncology in Skopje
    (Macedonian Academy of Sciences and Arts, 2023-01)
    ;
    Dragan Jakimovki
    ;
    Vladimir Ristovski
    Introduction: It is estimated that delays in diagnosis due to the COVID-19 pandemic in North Macedonia could result in significant reductions in the number of potentially curative stages in lung cancer patients. Purpose: The aim of this study was to review patient characteristics and treatment strategies of lung cancer patients treated at the University Clinic of Radiotherapy and Oncology (UCRO), during the pre-pandemic year (from 1 of March 2019 to the end of February 2020) and the pandemic year (from 1 of March 2020 to the end of February 2021). Material: We analyzed eligible patients in the course of these two years according to patient characteristics and treatment strategies. Results: We have a record increasing in number of undefined lung cancer patients without any patho logical or histological conformation (11% pandemic year compared to 7% in the previous year), and an increased number of stage III and IV NSCLC patients in the pandemic year 449 (87%), in comparison to the pre-pandemic year of 403 (74%) patients. We have found a decreasing number of stage II NSCLC patients in the pandemic year 82 (13%) compared to 141 (26%) patients in the pre-pandemic year. We also note a decreasing number of patients with NSCLC operated on from 218 to 123 in the pandemic group. Due to frequent check-ups for COVID-19, we report an increasing number of early stage IA and stage IB patients, treated only by surgery. Conclusions: The strict screening and admittance criteria put in place by hospitals during the pandemic might have improved the oncology treatment course of lung cancer patients.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Differences of Oncology Treatment for Lung Cancer Patients in Pandemic COVID-19 Year: Our Clinical Experience
    (IASLC, 2022-08)
    ;
    Crvenkova, L
    Introduction: It is estimated that in North Macedonia delays in diagnosis due to COVID-19 pandemic, could result in significant reductions in the number of potentially curative stages in lung cancer patients. Methods: The aim of this study was to evaluate patient characteristics and treatment strategy of lung cancer patients treated at the University Clinic of Radiotherapy and Oncology (UCRO), during the pre-pandemic year (from 1 of March 2019 to the end of February 2020) compared to pandemic year (from 1 of March 2020 to the end of February 2021). We analyzed eligible patients in the course of these two years according to the patient characteristics and treatment strategies. Results: We have record increasing in number of undefined lung cancer patients without any pathological or histological conformation (11% pandemic year compared to 7 % in the previous year), and increased number of stage III and IV NSCLC patients in pandemic year 449 (87%) patients of NSCLC, in comparison to the pre-pandemic year 403 (74%). We have found decreasing number of stage II NSCLC patients in pandemic year 82 (13%) compared to 141 (26%) patients in pre-pandemic year and reporting decreasing number of operated patients with NSCLC from 218 to the 123 in the pandemic group. But we have to report increasing number of early stage IA and stage IB patients total 16, treated only by surgery. Conclusions: The strict screening and admittance criteria instilled by hospitals during the pandemic might have improved oncology treatment courses of the lung cancer patients. Keywords: COVID-19, lung cancer, pandemic year
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Possitron Emisiot Tomography in the menagement of lung diseasses: Current Aplications and futures perspectives
    (Opca Bolnica Teshanj, 2021-10-30)
    ;
    ;
    Todevski D
    ;
    Tushevska-Mitkovska M
    ;
    Chamurovski N
    Positron emission tomography (PET) combined with computed tomography (CT) is an established diagnostic modality that has become an essential imaging tool in oncological practice. However, thanks to its noninvasive nature and its capability to provide physiological information, the main applications of this technique have significantly expanded. In the past 20 years, positron emission tomography (PET), usually with 18F-fluoro-2-deoxy-D-glucose (FDG), has become an important imaging modality in patients with lung cancer. PET is a useful technique to characterize the solitary pulmonary nodule, diagnose primary lung cancer, carry out mediastinal and extrathoracic staging, plan radiotherapy, therapeutic response assessment and detect recurrence. PET may help to determine the ideal site for tissue diagnosis as well as predict prognosis. Combined PET and computed tomography (PET / CT) has the best of both worlds of metabolic and anatomic imaging and may provide optimal disease assessment. 18F-labelled fluorodeoxyglucose (FDG) is the most commonly used radiopharmaceutical for PET scanning and demonstrates metabolic activity in various tissues. Since activated inflammatory cells, like malignant cells, predominantly metabolise glucose as a source of energy and increase expression of glucose transporters when activated, FDG-PET/CT can be successfully used to detect and monitor a variety of lung diseases, such as infections and several inflammatory conditions. The added value of FDG-PET/CT as a molecular imaging technique relies on its capability to identify disease in very early stages, long before the appearance of structural changes detectable by conventional imaging. Furthermore, by detecting the active phase of infectious or inflammatory processes, disease progression and treatment efficacy can be monitored.